Drug Profile
Pyridoxal phosphate - Medicure
Alternative Names: Avastrem; Cardoxal; MC-1; Pyridoxal 5'-phosphate; TardoxalLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Medicure
- Class Anti-ischaemics; Antiepileptic drugs; Coenzymes; Ischaemic heart disorder therapies; Picolines; Small molecules; Vascular disorder therapies
- Mechanism of Action Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Drug-induced dyskinesia
Highest Development Phases
- Phase III Seizures
- Phase II Drug-induced dyskinesia
- Discontinued Lipid metabolism disorders; Myocardial infarction; Reperfusion injury; Stroke
Most Recent Events
- 16 Feb 2024 Phase-III clinical trials in Seizures in USA (PO) (NCT04706013)
- 19 May 2023 Pyridoxal phosphate is still in preclinical development for Seizure associated with Pyridoxamine 5'-phosphate oxidase deficiency in Canada
- 28 Mar 2022 No recent reports of development identified for preclinical development in Seizures in Canada (IV, Injection)